Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Cell Line Authentication – V 2.0

Posted on By


Biosimilars: SOP for Cell Line Authentication – V 2.0


Standard Operating Procedure for Cell Line Authentication in Biosimilars

Department Biosimilars
SOP No. SOP/BS/030/2025
Supersedes SOP/BS/030/2022
Page No. Page 1 of 13
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To define the validated procedure for cell line authentication used in biosimilar production using genetic, morphological, and cytogenetic methods to confirm cell identity and prevent cross-contamination.

2. Scope

This SOP applies to all cell lines used in biosimilar R&D, MCB/WCB generation, and manufacturing, and covers STR profiling, species-specific PCR, and optional karyotyping and isoenzyme analysis.

3. Responsibilities

  • QC Molecular Analyst: Conducts STR, PCR, and other identity assays.
  • QA Officer: Verifies authenticity results and approves authentication records.
  • CLD Head: Ensures authentication is completed before use in production or submission.
See also  Biosimilars: SOP for Glycosylation Analysis in Clone Selection - V 2.0

4. Accountability

The Head of Quality Control is accountable for ensuring accurate identity testing of production cell lines and implementation of corrective actions in case of misidentification.

5. Procedure

5.1 Sample Collection

  1. Collect 3–5 × 106 cells from the test culture vial.
  2. Pellet cells and store at -80°C or proceed directly to DNA extraction.
  3. Record details in the Authentication Sample Log (Annexure-1).

5.2 STR Profiling (Human Cell Lines)

  1. Extract genomic DNA using silica column-based kits or magnetic beads.
  2. Amplify loci such as D5S818, D13S317, D7S820, TH01, vWA, CSF1PO using multiplex STR kits.
  3. Run samples on capillary electrophoresis and analyze alleles using fragment analysis software.
  4. Compare the STR profile with reference database or ATCC cell bank profile.

5.3 Species-Specific PCR (Non-Human Cell Lines)

  1. Use validated primers for species ID: CHO, HEK293, Vero, BHK, etc.
  2. Perform PCR under standardized conditions with positive/negative controls.
  3. Visualize products by gel electrophoresis.
See also  Biosimilars: SOP for Western Blotting for Protein Expression - V 2.0

5.4 Karyotyping (Optional)

  1. Arrest dividing cells with Colcemid.
  2. Prepare chromosome spreads and stain with Giemsa.
  3. Assess chromosomal number and structure under microscope (optional for regulatory submission).

5.5 Result Interpretation

  1. Identity confirmed when:
    • STR matches reference profile (≥ 80% match).
    • PCR result matches expected species band size.
    • No contamination bands or abnormal profiles are observed.
  2. Document results in Authentication Report (Annexure-2).

5.6 Frequency and Retesting

  1. Perform authentication:
    • Before MCB creation
    • After major scale-up or genetic modification
    • Every 6–12 months during ongoing use

6. Abbreviations

  • STR: Short Tandem Repeat
  • PCR: Polymerase Chain Reaction
  • MCB: Master Cell Bank
  • WCB: Working Cell Bank

7. Documents

  1. Authentication Sample Log (Annexure-1)
  2. Cell Line Authentication Report (Annexure-2)
See also  Biosimilars: SOP for Transformation and Electroporation - V 2.0

8. References

  • ICH Q5D – Cell Substrates
  • WHO TRS 978 – GMP for Cell Banks
  • ATCC Standards – Cell Line Authentication

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Authentication Sample Log

Date Sample ID Cell Line Method Analyst Remarks
03/05/2025 CL-BS-030 CHO-S Species PCR Rajesh Kumar Valid Profile

Annexure-2: Cell Line Authentication Report

Sample ID Cell Line Authentication Method Date Tested Result Approved By
CL-BS-030 CHO-S Species PCR 03/05/2025 CHO Identity Confirmed

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Updated STR loci list and added karyotyping step Expanded regulatory requirement
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: API Manufacturing: SOP for Jet Milling Operation – V 2.0
Next Post: BA-BE Studies: SOP for Use of Case Record Forms (CRFs) in Clinical Phase – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version